Nanordica Medical Raises €1.6M to Bring Antibiotic-Free Chronic Wound Treatment to Market

Why It Matters

Antibiotic‑free wound care could curb antimicrobial resistance while lowering costly complications for millions with chronic wounds, reshaping the diabetic foot ulcer market.

Key Takeaways

• Nanordica raised €1.6M (~$1.75M) to commercialize antibiotic‑free wound dressing.
• Premotiv cut wound area 43% in one week vs 13% silver.
• Multicenter trial enrolls 120+ DFU patients, targeting reimbursement and guideline adoption.
• CE marking and European patent secured, enabling EU commercial launch.
• €2.4M (~$2.6M) EIC Accelerator grant backs trial and product rollout.

Pulse Analysis

Chronic wounds affect roughly 100 million people worldwide, with diabetic foot ulcers (DFUs) accounting for the majority of infections, amputations and mortality. Traditional care relies on systemic antibiotics, which often fail to reach the wound bed and fuel the growing crisis of antimicrobial resistance. The economic burden mirrors that of oncology, prompting investors and regulators to seek safer, more effective alternatives that can cut treatment costs and improve patient outcomes.

Nanordica Medical’s Premotiv technology tackles this dilemma by integrating antimicrobial activity with a skin‑cell‑friendly matrix, eliminating the need for antibiotics. In a randomized controlled trial of 30 DFU patients, Premotiv achieved a 43% reduction in wound size after just seven days, compared with a 13% reduction using conventional silver dressings. The company’s ongoing multicenter, double‑blind study—now enrolling over 120 participants—aims to provide the robust clinical evidence required for reimbursement and inclusion in wound‑care guidelines, potentially accelerating adoption across hospitals and specialty clinics.

The recent €1.6 million financing round, complemented by a €2.4 million EU Innovation Council grant, will fund the completion of the pivotal trial and secure CE marking for the European market. With a granted European patent and an existing veterinary product already distributed in six countries, Nanordica is positioned to launch its human dressing swiftly. Successful market entry could reshape chronic wound management, offering a scalable, antibiotic‑free solution that aligns with global health priorities and delivers measurable cost savings.